TriSalus Life Sciences held its 2026 Annual Meeting where shareholders elected two directors, ratified Grant Thornton as auditors, approved three-year say-on-pay frequency, and approved executive compensation.
Key takeaways
67.9% of outstanding shares (41,728,676) represented at the Annual Meeting.
Mary Szela and Gary Gordon elected as directors for three-year terms expiring in 2029.
Grant Thornton ratified as independent auditors for fiscal year ending December 31, 2026.
Three-year frequency for future say-on-pay votes approved; Board adopted every three years.
Named executive officer compensation approved on advisory basis.